
Almirall appoints first woman to its Board
pharmafile | November 21, 2012 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Almirall
Karin Louise Dorrepaal is the first woman to join Almirall’s ten-member Board of directors.
Dorrepaal, who is Dutch, has extensive international experience in the pharmaceutical sector and in consultancy. The appointment takes effect as of 1 January and will be ratified in Almirall’s next Annual General Meeting.
Dorrepaal’s career spans over 25 years during which she has held top-level positions in the pharmaceutical sector and the international strategic consultancy area.
She has led various pharmaceutical business model transformation processes and currently holds non-executive positions in companies related to the healthcare sector and consultancy.
Related Content

Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment
Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk …

Almirall gains EC approval of Ebglyss for moderate-to-severe atopic dermatitis
Almirall has announced that the European Commission (EC) has approved Ebglyss (lebrikizumab) for the treatment …
Almirall: The New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD) publish Ph3 data evaluating lebrikizumab efficacy and safety in moderate-to-severe atopic dermatitis
BARCELONA, Spain. March 31, 2023 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on …






